Careers  |  Sign In  |  Register

Visual Acuity Improved With Prophylactic Bevacizumab for Uveal Melanoma


Results from a cohort study suggest that vision loss, a common side effect after plaque radiotherapy for uveal melanoma, may be mitigated or avoided entirely thanks to prophylactic anti-vascular endothelial growth factor treatment. By employing intravitreal bevacizumab patients had better outcomes compared with the control group.

Learn more by clicking here.